Ying LI, Jiali LIU, Xintong WANG, Guifang CHEN
Alpha Psychiatry - 2026;27(5):46465-0
Background: Depression is a psychiatric disorder characterized by mood disturbances and cognitive impairment. Existing treatments, such as pharmacotherapy and cognitive-behavioral therapy (CBT), often present limitations, including delayed onset of efficacy and low adherence. Eye Movement Desensitization and Reprocessing (EMDR), a psychotherapy originally developed for post-traumatic stress disorder (PTSD), has shown potential in the treatment of depression. Methods: This systematic review synthesized evidence from 27 studies (14 randomized controlled trials, 10 single-arm studies, and three controlled studies) published between January 1990 and December 2024, integrating both behavioral outcomes and findings on neural mechanisms. Literature searches were conducted in PubMed, Web of Science, and ScienceDirect. Results: The findings indicate that EMDR demonstrates potential efficacy in alleviating depressive symptoms. The included studies involved diverse populations, including individuals with major depressive disorder, comorbid conditions, and trauma exposure, suggesting potential applicability across a range of clinical contexts. Preliminary neurobiological evidence has explored possible mechanisms involving modulation of prefrontal-limbic circuits and the integration of traumatic memories, providing initial insights into its therapeutic effects. Conclusions: Current evidence supports EMDR as a promising intervention for depression. However, further large-scale, high-quality studies are required to confirm its generalizability, identify optimal target populations, and clarify its underlying neurobiological mechanisms.
